Ovagen
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
What is it?
Ovagen is a Khavinson tripeptide the source directory profiles for liver and GI tissue — hepatocyte function and GI mucosal health. Despite the name, it is not an ovarian-tissue peptide. It’s part of the digestive/hepatic corner of the Khavinson short-peptide bioregulator family, alongside Pancragen and Livagen.
What does it do in my body?
Claimed mechanism: like the rest of the Khavinson family, Ovagen is proposed to modulate gene expression in a tissue-specific way — here, supporting hepatocyte function and GI mucosal integrity. There is no Ovagen-specific mechanistic study to cite beyond the general family-level theoretical claim.
How can it help me?
- Where the science stands: Directory lists “Emerging” (22 studies, 1 human) — but all 22 are a name-collision with veterinary superovulation literature, not real peptide evidence. Actual base: effectively empty, framework-level only
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
No adverse-event data exists for Ovagen specifically. The family-wide reported profile in the Russian literature is mild and uncommon: occasional injection-site reactions, transient mild headache early in a cycle.
The real risk isn’t the molecule — it’s the supply chain. Khavinson-family peptides are the dominant gray-market counterfeit category in the peptide space. Ovagen’s name-collision problem makes it a particularly good case study for why citation verification matters — a seller citing “22 studies” for this peptide is citing the wrong literature entirely. Third-party COA verification matters more here than for almost any other peptide class.
Regulatory status: Ovagen is research_only in the US — not FDA-approved for human use, sold as a research compound, not eligible for compounding. It is not a controlled substance.
Typical dosing
Educational context only — talk to a licensed medical provider before any protocol. What follows describes the doses and schedules most commonly reported in the research and by practitioners, shared so you can have an informed conversation. These compounds are sold for research use only, are not FDA-approved drugs, and this is not medical advice.
Educational purposes only — this reflects the Khavinson-school protocol convention shared across the family; it is not medical advice.
There is no dosing or cycling data specific to Ovagen — the 22 “citations” are not real peptide evidence, so there is no dose-finding work to draw on. What exists is only the generic Khavinson-family cycle pattern: a short course of 10–20 days, repeated 2–3 times per year, with synthetic short peptides in the family generally dosed around ~100–200 mcg/day — but none of this has been validated for Ovagen specifically.
What should I avoid combining — and what's synergistic?
Ovagen doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
Where do people source this?
OHM does not sell or handle any compound. Research-use-only material is sold by third-party vendors; our vetting notes and disclosures are on the Where to buy page. If you'd rather have a physician in the loop, see the telehealth option. Whatever the route, the supply chain is the real risk: only consider vendors that publish batch-level third-party Certificates of Analysis.
Ovagen is a Khavinson tripeptide for liver and GI tissue — despite the name, NOT ovarian tissue. The 22 citations the source directory attaches to it are a name-collision with bovine/ovine/caprine superovulation veterinary literature, not real evidence for this peptide. Read that correction first; it’s the honesty-critical fact about this compound.
| Class | Khavinson tripeptide — sequence; targets liver and GI tissue |
| Mechanism (one line) | Claimed to support hepatocyte function and GI mucosal health via the family’s gene-modulation mechanism |
| Evidence base | Directory lists “Emerging” (22 studies, 1 human) — but all 22 are a name-collision with veterinary superovulation literature, not real peptide evidence. Actual base: effectively empty, framework-level only |
| Safety record | No AE data specific to Ovagen; family-wide mild profile assumed; OHM grade D / provisional |
| Regulatory status | research_only in the US, not FDA-approved |
What it is
Ovagen is a Khavinson tripeptide the source directory profiles for liver and GI tissue — hepatocyte function and GI mucosal health. Despite the name, it is not an ovarian-tissue peptide. It’s part of the digestive/hepatic corner of the Khavinson short-peptide bioregulator family, alongside Pancragen and Livagen.
How it works
Claimed mechanism: like the rest of the Khavinson family, Ovagen is proposed to modulate gene expression in a tissue-specific way — here, supporting hepatocyte function and GI mucosal integrity. There is no Ovagen-specific mechanistic study to cite beyond the general family-level theoretical claim.
What the research shows
Important source caveat. The 22 studies the directory attaches to Ovagen are all bovine/ovine/caprine superovulation and embryo-production papers (FSH, follicular dynamics in ewes and beef cows) — a clear name-collision between “Ovagen” the Khavinson liver peptide and “ovagen/ovulation” veterinary reproduction literature that the directory auto-matched. None of those citations are evidence for the Ovagen peptide.
The honest read: the Ovagen peptide’s actual human/preclinical evidence base is effectively empty; treat it as framework-level only, like Livagen. Flagged and corrected here rather than repeated. (This name-collision is also why the peptide gets grouped under both “digestive” and “reproductive” in some build materials — the name straddles both, but the peptide is the liver/GI one.)
OHM grade: D / provisional.
Real-world protocol
Educational purposes only — this reflects the Khavinson-school protocol convention shared across the family; it is not medical advice.
There is no dosing or cycling data specific to Ovagen — the 22 “citations” are not real peptide evidence, so there is no dose-finding work to draw on. What exists is only the generic Khavinson-family cycle pattern: a short course of 10–20 days, repeated 2–3 times per year, with synthetic short peptides in the family generally dosed around ~100–200 mcg/day — but none of this has been validated for Ovagen specifically.
Side effects & management
No adverse-event data exists for Ovagen specifically. The family-wide reported profile in the Russian literature is mild and uncommon: occasional injection-site reactions, transient mild headache early in a cycle.
The real risk isn’t the molecule — it’s the supply chain. Khavinson-family peptides are the dominant gray-market counterfeit category in the peptide space. Ovagen’s name-collision problem makes it a particularly good case study for why citation verification matters — a seller citing “22 studies” for this peptide is citing the wrong literature entirely. Third-party COA verification matters more here than for almost any other peptide class.
Regulatory status
Ovagen is research_only in the US — not FDA-approved for human use, sold as a research compound, not eligible for compounding. It is not a controlled substance.
Sources
- primary profile (thepeptidelist.com directory capture, 2026-06-07).
- 0035 tier/safety/goal grading: Ovagen kept D-provisional / encyclopedia-only.
- Note: the directory’s 22 cited studies are bovine/ovine/caprine superovulation veterinary literature — a name-collision, not evidence for this peptide (flagged, not itemized as citations here).
- Related: Pancragen · Livagen · the Khavinson bioregulator family.
Sources & references
- primary profile (thepeptidelist.com directory capture, 2026-06-07).
- 0035 tier/safety/goal grading: Ovagen kept D-provisional / encyclopedia-only.
- Note: the directory’s 22 cited studies are bovine/ovine/caprine superovulation veterinary literature — a name-collision, not evidence for this peptide (flagged, not itemized as citations here).
- Related: Pancragen · Livagen · the Khavinson bioregulator family.